Strabismus is a misalignment of the visual axes, due to an imbalance in extraocular muscle (EOM) function. Botulinum neurotoxin (BoNT) treatment can correct the misalignment with permanent therapeutic effects in infants, possibly because the toxin causes structural alterations in developing EOM. To determine whether BoNT indeed permanently weakens developing EOMs, we examined the chicken oculomotor system. Following injections of BoNT in hatchling chicks, we quantified physiological parameters (contractile force measurements) and morphological parameters (myofiber morphometry, innervation, quantitative transmission electron microscopy of mitochondria/fiber types). Treatment of developing EOM with BoNT caused acute reductions of muscle strength and mitochondrial densities, but minimal changes in muscle fiber diameter and neuromuscular junction structures. Contrary to expectations, contractile force was fully recovered by 3-4 months after treatment. Thus, permanent therapeutic effects of BoNT most likely do not cause permanent changes at the level of the peripheral effector organ, but rather involve central (CNS) adaptive responses.
Introduction
Strabismus is a misalignment of the visual axes, due to an imbalance in extraocular muscle (EOM) function. Precise muscle force regulation is required to align the eyes for coordination of functional and binocular vision. Failure to maintain proper visual alignment results in a condition known as strabismus. Strabismus is one of the most prevalent ophthalmic disorders, affecting nearly 5% of the human population (Magramm, 1992; Stidwill, 1997; Tychsen, 2005) . Infantile (pediatric or congenital) strabismus begins during the first year of life (Tychsen, 2005) . Early treatment of infantile strabismus is particularly important because visual alignment is required for proper binocular vision development and stereopsis (Hubel and Wiesel, 1965; Ing, 1981; Fenstemaker et al., 2001; Kind et al., 2002) . Eye misalignment during this critical period can disrupt binocular fusion and may lead to amblyopia (permanent loss of vision in one eye) through the neural mechanism of suppression (Birch et al., 1990) .
In the early 1970s, Scott and colleagues pioneered the use of botulinum neurotoxin (BoNT) as an effective alternative to conventional strabismus surgery (Scott et al., 1973) . Since this time, BoNT has been effectively used for eye realignment in children and adults, but its use has been limited due to its relatively short duration of action, which often necessitates reinjection or transition to incisional surgery (Scott, 1980; Lee et al., 1988; Biglan et al., 1989; Ing, 1993; Tejedor and Rodriguez, 2001) . In contrast, the application of BoNT in the treatment of pediatric strabismus, particularly infantile esotropia, has demonstrated permanent therapeutic results, but the effectiveness is related to the age at which the treatment is performed. Administration before the critical age of 7 months resulted in the lowest recurrence of esodeviation, whereas treatment after the age of 8 months did not provide the expected "stable" outcome and required additional applications (Magoon, 1989; Campos et al., 2000; McNeer et al., 2000 McNeer et al., , 2003 .
These results suggest that the toxin may have permanent muscleweakening effects in developing EOM (Campos et al., 2000) . However, it is also possible that the toxin-induced changes are transient and the lasting therapeutic effects may involve central adaptive responses that "self-adjust" to maintain the stable binocular state (Campos et al., 2000; Tychsen, 2005) . Although about 300 million people worldwide would benefit from BoNT treatment for eye alignment during their first year of life, the principal mechanism of action of this therapy in the oculomotor system is unknown, and the physiological and structural effects of the toxin during the relevant early phase of EOM development have not been examined. While a primate model system would theoretically be optimal for this task, it is prohibitively expensive to use adequate numbers of monkeys necessary for conclusive statistical analyses (e.g., Spencer and McNeer, 1987; Spencer et al., 1992) . Mice and other rodents, while less costly, have relatively small eyes and make it technically difficult to manipulate EOMs for contractile force measurements. To conclusively determine BoNT's effects during development, an additional model system is needed that is both cost-effective and
